Investors and Media

Investor Relations

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Cancer is one of the most difficult diseases to treat. It is constantly changing, requiring new and more sophisticated therapies.

Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response.

Oncolytic immunotherapy enhances the effectiveness of immune checkpoint blockade and is expected to become the second cornerstone of immuno-oncology (IO) approaches, moving beyond incremental improvements in cancer treatment to help more patients overcome their disease.

Press Releases
Apr 07, 2024
RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patients SAN DIEGO , April 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company